StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Abbvie (ABBV): IPR Victory Translates Into A 36% PT Increase - Cowen
September 11, 2017 6:16 AM
Cowen analyst, Steve Scala, reiterated his Outperform rating on shares of Abbvie (NYSE: ABBV) and raised his price target to ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst PT Change
Next Articles
Near-Term Bullish Options Activity in AbbVie (ABBV) Targets Upside Above $90 Amid Rally in Shares -Susuqehanna
September 13, 2017 1:55 PM
Speculative Bullish Options Flow in AbbVie (ABBV) as Management Presents at Healthcare Conference -Susquehanna
September 12, 2017 2:33 PM
AbbVie (ABBV) Reports Upadacitinib (ABT-494) Meets All Primary & Ranked Secondary Endpoints in Second Phase 3 Study
September 11, 2017 8:03 AM